Can any stem-cell paper be trusted?

So, just how untrustworthy is the stem-cell literature? Very, according to one of the field's leading lights, David Shaywitz of the Harvard Stem Cell Institute. He's the author of linkurl:an op-ed piece;http://www.washingtonpost.com/wp-dyn/content/article/2006/01/11/AR2006011102040.html that was meant to defend the beleaguered field of stem-cell research, despite linkurl:fraudulent papers;http://www.the-scientist.com/blog/browse/blogger/13/date/2006-01/ from the lab of Korean researcher Hwang

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
So, just how untrustworthy is the stem-cell literature? Very, according to one of the field's leading lights, David Shaywitz of the Harvard Stem Cell Institute. He's the author of linkurl:an op-ed piece;http://www.washingtonpost.com/wp-dyn/content/article/2006/01/11/AR2006011102040.html that was meant to defend the beleaguered field of stem-cell research, despite linkurl:fraudulent papers;http://www.the-scientist.com/blog/browse/blogger/13/date/2006-01/ from the lab of Korean researcher Hwang Woo Suk. But in what was almost an aside, Shaywitz dropped a bombshell:**While most in the field of stem cell research were shocked by the reports of fraud, the shock was only one of degree; it is common knowledge that the bar for publication in this field often has appeared remarkably low, with even well-respected research journals seeming to fall over one another for the privilege of publishing the next hot paper. The result of this frenzy has been an entire body of literature that is viewed with extreme skepticism by most serious stem cell investigators.**It was a bombshell to me, anyway. There is plenty of gossip among science journalists about how the top journals--you know who you are--engage in savage battles to be first with the latest in a handful of hot research fields. And that they define **hot** to mean papers that will grab headlines on TV news and in the New York Times. The Scientist's Ivan Oransky brought this topic up in linkurl:his blog;http://www.the-scientist.com/blog/display/22934/ Tuesday. Scientists grumble too, only not usually for quotation. But this is the first time I've seen a prominent researcher declaring that this unseemly competition has cast doubt--not just on an individual paper or two, but on an entire literature.What is to be done? Must stem-cell researchers conduct their own lab peer review, replicating every bit of each others' work before they try to build on it? Are there structural changes at journals that will help ensure that papers are reporting accurately? The editor of Science, linkurl:Donald Kennedy, says;http://www.sciencemag.org/sciext/hwang2005/kennedy_20060110_transcript.pdf his journal (which published the two fraudulent Hwang papers, now retracted) is considering adding some measures such as improved image analysis. But overall, he doesn't sound optimistic that procedural safeguards will make much difference.Kennedy goes on to argue that such cases are rare. But that's just the point. If we are to believe Shaywitz, in stem-cell research at least, they are not rare at all.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Tabitha M. Powledge

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo